Alternative Data for Agenus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 54 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 56 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 171 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,448 | Sign up | Sign up | Sign up |
| X Followers | 2,715 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 19 | Sign up | Sign up | Sign up |
| Linkedin Employees | 195 | Sign up | Sign up | Sign up |
About Agenus
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer.
| Price | $3.58 |
| Target Price | Sign up |
| Volume | 621,821 |
| Market Cap | $149M |
| Year Range | $2.77 - $5.07 |
| Dividend Yield | 0% |
| PE Ratio | 1.75 |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal CancerApril 1 - Financial Post |
|
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues RecognizedMarch 16 - Financial Post |
|
Agenus Data From Phase 1b C-800-01 Study Evaluating Botensilimab Shows Survival With BOT+BAL Associated With Systemic Inflammation In Blood, Tumor Immune Activity Within Tumor MicroenvironmentFebruary 19 - Benzinga |
|
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold TumorsFebruary 9 - Financial Post |
|
Agenus To Highlight New Data At AACR-IO Exploring Systemic And Tumor Inflammation Biomarkers With BOT/BAL In Immunologically Cold TumorsFebruary 8 - Benzinga |
|
 |
Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives TranscriptJanuary 28 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 34M | 600,000 | 34M | -11M | 15M | 0.681 |
| Q3 '25 | 30M | 24M | 6M | 64M | 80M | 1.940 |
| Q2 '25 | 26M | 27M | -1.3M | -28M | -14M | -1.000 |
| Q1 '25 | 24M | 22M | 2.4M | -25M | -10M | -1.030 |
| Q4 '24 | 27M | 34M | -7.1M | -46M | -23M | -2.040 |
Insider Transactions View All
| ARMEN GARO H filed to buy 625,969 shares at $0.6. February 15 '24 |
| WIINBERG ULF filed to buy 124,063 shares at $0.8. November 17 '23 |
| O'Day Steven J filed to sell 61,321 shares at $3.1. January 6 '22 |
Similar companies
Read more about Agenus (AGEN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Agenus
The Market Cap of Agenus is $149M.
As of today, Agenus' PE (Price to Earnings) ratio is 1.75.
Currently, the price of one share of Agenus stock is $3.58.
The AGEN stock price chart above provides a comprehensive visual representation of Agenus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Agenus shares. Our platform offers an up-to-date AGEN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Agenus (AGEN) does not offer dividends to its shareholders. Investors interested in Agenus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Agenus are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
